These negotiated prices are on some of the most frequently dispensed and expensive drugs in the Medicare program, including cardiovascular-related drugs Eliquis, Xarelto and Entresto and Type 2 Diabetes drugs Jardiance, Januvia and Farxiga. Other reforms in the law include capping the cost of insulin at $35 a month for seniors and free vaccines for the prevention of common illnesses such as shingles and the flu. Both of these are already in effect.
Here are just a few examples of what these lower prescription drug prices actually mean:
- Prices for Enbrel, a prescription that treats rheumatoid arthritis, will be reduced by 67 percent. That’s a savings of $4,751 for the list price of a 30-day supply.
- Costs for Imbruvica, a medicine for people with blood cancers, will be reduced by 38 percent. That’s a savings of $5,615 for the list price of a 30-day supply.
- The cost of Stelara, a treatment for psoriasis and Crohn’s disease, will go down by two-thirds. That’s a savings of $9,141 for the list price of a 30-day supply.
What this means is that nearly 829,800 Pennsylvanians and 29,000 people in our District enrolled in Medicare Part D will see lower prices beginning January 1, 2026. Specifically, in our community, this means a cumulative $9 million in savings for out-of-pocket costs, with projected increases to $20.8 million by the end of next year.
It was an honor to work with Vice President Harris and President Biden to support the Inflation Reduction Act and bring relief to people in our District, and we will continue this work on your behalf.
Click here to learn more about the new law and how you can save.
If you have any questions about Medicare prescription drug pricing, please reach out to my office. We’re here to help.
